Today Vitrolife is publishing the Annual Report 2014 (in Swedish) and the Summary Annual Report 2014 (in English). The documents are attached to this press release and are also available on www.vitrolife.com (http://www.vitrolife.com/en/Corporate/). The summary is a shorter document that summarises the main points in the Annual Report 2014, but is not a substitute for it and does not contain all the information needed to give as full an under-standing of the Group’s performance, financial position and future prospects as is provided by the Annual Report 2014, which can be downloaded on www.vitrolife.com (http://www.vitrolife.com/en/Corporate/). Distribution of the printed versions of the annual reports to those shareholders who have requested dispatch, will be done by mail during the week commencing 20 April. The printed version of the Annual Reports can be ordered on the company's website www.vitrolife.com (http://www.vitrolife.com/en/Corporate/), by phone +46 (0)31 721 80 00 or by email info@vitrolife.com. Gothenburg, Sweden April 13, 2015 VITROLIFE AB (publ) Queries should be addressed to: Mikael Engblom, CFO, tel 46 31 721 80 14 Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 13, 2015 at 11:00 a.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. ________________________________________________________________________________ _ ________________________________ Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 330 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE 1 3469), Mid Cap. Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
Annual Report 2014
| Source: Vitrolife AB
Attachments
